Tremfya

Chemical Nameguselkumab
Dosage FormInjection (subcutaneous; 100 mg/mL)
Drug ClassMonoclonal antibodies
SystemSkin
CompanyJanssen Biotech
Approval Year2017

Indication

  • For the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Last updated on 10/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tremfya (guselkumab) Prescribing Information2019Janssen Biotech, Inc., Horsham, PA
Document TitleYearSource
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.2019Journal of the American Academy of Dermatology